Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

Kinan Alhallak, Amanda Jeske, Pilar De La Puente, Jennifer Sun, Mark A. Fiala, Feda Azab, Barbara Muz, Ilyas Sahin, Ravi Vij, John F. DiPersio, Abdel Kareem Azab

Blood (2021) 138 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2021-153832

Published: 2021

Journal Articles

3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients

Amanda Jeske, BS, Feda Azab, BPharm, Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Justin King, Daniel R. Kohnen, MBA, Ravi Vij, MBBS, Abdel Kareem Azab, PhD

Blood (2018) 132 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2018-99-118888

Published: 2018

Journal Articles

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Pilar De La Puente, PhD M.Sc, Abbey Jin, Micah John Luderer, BS, MS, Christopher Egbulefu, Barbara Muz, PhDMSc, Cinzia Federico, PhD, Justin King, Daniel Kohnen, Noha Nabil Salama, PhD, Samuel Achilefu, Ravi Vij, MDMBA, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 1876.

https://doi.org/10.1182/blood.V130.Suppl_1.1876.1876

Published: 2017

Journal Articles

Plasma-Derived 3D Culture for Leukemic Proliferation

Pilar De La Puente, PhD M.Sc, Ryan Soo Hoo, Michael P Rettig, PhD, Noha Nabil Salama, PhD, John F DiPersio, MD PhD, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 3831.

https://doi.org/10.1182/blood.V130.Suppl_1.3831.3831

Published: 2017

Journal Articles

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Pilar De La Puente, PhD, Abbey Jin, Micah John Luderer, BS, MS, Barbara Muz, PhD MSc, Justin A King, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2135.

https://doi.org/10.1182/blood.V128.22.2135.2135

Published: 2016

Journal Articles

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Barbara Muz, PhD MSc, Pilar De La Puente, PhD, Justin A King, Daniel R Kohnen, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2016) 128 (22): 2076.

https://doi.org/10.1182/blood.V128.22.2076.2076

Published: 2016

Journal Articles

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, BPharm, Micah John Luderer, BS, MS, Jack L. Arbiser, MD, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2978.

https://doi.org/10.1182/blood.V126.23.2978.2978

Published: 2015

Journal Articles

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Pilar De La Puente, PhD, Ellen Weisberg, MD, Atsushi Nonami, MDPhD, Micah John Luderer, BS, MS, Richard M. Stone, MD, Junia V. Melo, MD PhD, James D Griffin, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3694.

https://doi.org/10.1182/blood.V126.23.3694.3694

Published: 2015

Journal Articles

Tirapazamine As a Strategy to Overcome Hypoxia-Induced Drug Resistance in Multiple Myeloma

Barbara Muz, PhDMSc, Pilar De La Puente, PhD, Micah John Luderer, BS, MS, Farideh Ordikhani, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 4436.

https://doi.org/10.1182/blood.V126.23.4436.4436

Published: 2015

Journal Articles

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

Barbara Muz, PhDMSc, Joseph Abraham, Feda Azab, BPharm, Pilar De La Puente, PhD, Nicholas Potter, Benjamin Minch, Farideh Ordikhani, Noha Salama, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 1286.

https://doi.org/10.1182/blood.V126.23.1286.1286

Published: 2015

Journal Articles

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Justin King, Micah John Luderer, BS, MS, Ravi Vij, MD MBA, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 2985.

https://doi.org/10.1182/blood.V126.23.2985.2985

Published: 2015

Journal Articles

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Barbara Muz, PhDMSc, Feda Azab, BPharm, Pilar De La Puente, PhD, Yosef Landesman, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2015) 126 (23): 3017.

https://doi.org/10.1182/blood.V126.23.3017.3017

Published: 2015

Journal Articles

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

Pilar De La Puente, PhD, Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 2069.

https://doi.org/10.1182/blood.V124.21.2069.2069

Published: 2014

Journal Articles

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Pilar De La Puente, PhD, Feda Azab, B.Pharm, Barbara Muz, PhDMSc, Justin King, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4705.

https://doi.org/10.1182/blood.V124.21.4705.4705

Published: 2014

Journal Articles

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Scott A Rollins, PhD, Richard Alvarez, MBA, Ziad Kawar, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4758.

https://doi.org/10.1182/blood.V124.21.4758.4758

Published: 2014

Journal Articles

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 3011.

https://doi.org/10.1182/blood.V122.21.3011.3011

Published: 2013

Journal Articles

Hypoxia Induces Drug Resistance In Multiple Myeloma

Barbara Muz, PhD, MSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Irene M. Ghobrial, MD, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 1852.

https://doi.org/10.1182/blood.V122.21.1852.1852

Published: 2013

Journal Articles

PI3K-Alpha Plays A Major Role In Multiple Myeloma and Its Inhibition With BYL917 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance

Feda Azab, B.Pharm, Shireen Vali, Nicholas Potter, Joseph Abraham, Barbara Muz, PhD, MSc, Pilar De La Puente, PhD, Taher Abbasi, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 3215.

https://doi.org/10.1182/blood.V122.21.3215.3215

Published: 2013

Journal Articles

Autologous 3D Tissue-Engineered Bone Marrow For Drug Screening In MM Patients

Pilar De La Puente, PhD, Feda Azab, B.Pharm, Barbara Muz, PhD, MSc, Ravi Vij, MD, Abdel Kareem Azab, BPharm, PhD

Blood (2013) 122 (21): 132.

https://doi.org/10.1182/blood.V122.21.132.132

Published: 2013

NARROW

3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma

3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients

Enhancing Proteasome-Inhibitory Activity and Specificity of Bortezomib By Endocytosis-Mediated Uptake of CD38 Targeted Nanoparticles in Multiple Myeloma

Plasma-Derived 3D Culture for Leukemic Proliferation

Anti-CD38 Targeted Nanoparticles for Drug Delivery in Multiple Myeloma

Novel Flow Cytometry-Based Biomarkers Predict Recurrence in Myeloma Patients through Detection of MRD in the Bone Marrow and CTCs in Peripheral Blood

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma

Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia

Tirapazamine As a Strategy to Overcome Hypoxia-Induced Drug Resistance in Multiple Myeloma

Hypoxia Induces Pgp-Mediated Carfilzomib Resistance in Multiple Myeloma Cells and HIF Inhibition Significantly Enhances Sensitivity and Response to Carfilzomib In Vivo

Novel Method to Detect Minimal Residual Disease in Multiple Myeloma Predicts Recurrence Better Than CD138-Based Models

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma

Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia

Hypoxia Induces Drug Resistance In Multiple Myeloma

PI3K-Alpha Plays A Major Role In Multiple Myeloma and Its Inhibition With BYL917 Decreases Proliferation, Synergizes With Other Therapies and Overcomes Stroma-Induced Resistance

Autologous 3D Tissue-Engineered Bone Marrow For Drug Screening In MM Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only